FY27 Growth Play: First Print Post ₹1,700 Cr Capital Raise—Watch Margin Resilience
Belrise reports Q1 FY27 as the first quarter after closing a ₹1,700 crore QIP and acquiring Hyva's tipper body business. Street expects flat-to-mid-single-digit revenue growth with stable margins, but guidance momentum on 4W/CV expansion and FY27 targets will define the thesis.
The Setup: Capital Deployment & FY27 Ramp
Belrise is reporting Q1 FY27 as the first quarter after a transformative capital raise and bolt-on M&A. The ₹1,700 crore QIP (closed July 17 at ₹220/share) and the near-simultaneous Hyva India Tipper Body acquisition (USD 5.65 million, ~3.6× EV/EBITDA) signal management's conviction on 4-wheeler and commercial-vehicle segment growth. The Q1 print will reveal how quickly these deployments translate into incremental revenue and whether margin resilience holds amid OEM pricing discipline and commodity volatility. On-plan expectations: revenue tracking the ₹2,110–₹2,427 Cr guidance range (~5–10% YoY growth); EBITDA margin holding ~11–13% (vs. 12.4% in Q1 FY26); PAT in the ₹136–₹173 Cr band. Street consensus favours the buy thesis—HSBC initiated Buy at ₹270 (aerospace/defence upside), Jefferies targets ₹250 (M&A-led growth)—but the stock is technically overbought (RSI 77.1), leaving little room for guided prints to disappoint.
~₹2,150–2,350 Cr
Street midpoint of ₹2,110–2,427 Cr guide; ~7% YoY on Q1 FY26 base (~₹2,010 Cr implied)
~11–13%
In line with Q1 FY26 (12.4%); commodity/OEM pricing to be monitored
~₹136–173 Cr
Street range; mid-point ~₹155 Cr implies ~15% YoY growth (vs. ~₹135 Cr Q1 FY26)
Likely interim
Board approved ₹0.55 final dividend for FY26; Q1 interim expected
What a Strong vs. Weak Print Looks Like
A strong print: Revenue growth at or above the 7–10% YoY midpoint (₹2,200+ Cr), EBITDA margin holding 12%+, and confident FY27 guidance reiterating 40–45% 4W/CV revenue growth. Management commentary on Hyva integration milestones and aerospace/defence traction. Dividend in line with historical 1–2% yield. A weak print: Revenue miss (below ₹2,100 Cr) or margin compression below 11% (signalling OEM pricing pressure or trading-business dilution). Equivocal guidance on FY27 target achievement; any mention of macro headwinds or capex delays. Insider/promoter shareholding changes post-QIP (current: promoter 61.15%, down from 66.46% pre-QIP).
On Track? The Guidance Test
In May 2026, Belrise reported FY26 revenue of ₹9,509 Cr (+14.7% YoY) and PAT of ₹502 Cr (+41.2% YoY)—a strong exit with diversification narrative (aerospace, defence, 4W expansion). Management flagged a 40–45% revenue growth target for 4W/CV for FY27, supported by the just-closed ₹1,700 crore capital raise. Q1 FY27 is the proof-of-concept: if 4W orders are flowing and capex is deploying on schedule, we expect to see sequential revenue momentum (Q4 FY26 was ~₹2,400 Cr; Q1 FY27 ~₹2,150–2,350 Cr would imply a seasonal dip, but guidance commentary will clarify full-year momentum). The Hyva acquisition (~3.6× EV/EBITDA, accretive from day 1) is a low-risk bolt-on; integration updates will be watched. Watch for any margin pressure from trading-business mix and commodity inflation.
Since Last Quarter
1 · ₹1,700 Cr QIP (Jul 17) — Capital Deployment & Dilution
Successfully closed QIP on July 17 at ₹220/share (4.68% discount to ₹230.79 floor). Raised ₹1,700 Cr to fund 4W/CV expansion, aerospace/defence vertical, and working capital. Shareholding dilution: promoter stake fell from 66.46% (FY27 Q1) to 61.15% (FY27 Q2), while FII (+2.7pp to 12.10%) and DII (+3.11pp to 13.12%) added. No insider selling flagged; promoter buying support expected if Q1 prints well.
2 · Hyva India Tipper Body Acquisition (Aug 4) — Strategic M&A
Board approved acquisition of Hyva (India) Pvt. Ltd.'s India Tipper Body business for ~USD 5.65 million (~₹47 Cr) via slump sale. Multiple of ~3.6× EV/EBITDA is attractive; transaction is accretive from day 1. Expands CV/commercial-vehicle capabilities; expected to contribute from Q1 onward. Integration milestones to watch in management commentary.
3 · Amalgamation Scheme — Regulatory Sign-Off (Jul 4)
NSE and BSE issued observation letters for the proposed Scheme of Amalgamation with Badve Autocomps Private Limited and Eximius Infra Tech Solutions Private Limited. No financial impact expected in Q1; regulatory milestone cleared. Implementation timeline TBD; watch for updates.
4 · Trading Window & Insider Compliance (Jun 29)
Trading window closure announced for designated persons, effective until results announcement. Routine compliance measure; no material insider activity flagged pre-blackout.
5 · EUR 2.75 Mn Guarantee for Subsidiary (Jun 30)
Corporate guarantee issued to Standard Chartered for subsidiary ECB facility (EUR 2.5 Mn). Routine operational; no material impact on Q1 numbers expected.
6 · Bulk Deal: ₹213.33/share (Apr 17)
Jainam Broking offloaded 46 lakh shares @ ₹213.33 (pre-QIP). No promoter/insider link noted; routine broker repositioning. Settled well below current ₹253.97.
The Watch List: Result Day
1 · 4W/CV Segment Traction
Management reiterated 40–45% revenue growth for 4W/CV in FY27; Q1 narrative will clarify order book health and capex deployment pace. Watch for customer wins, capacity ramp, and pricing commentary (OEM negotiations ongoing). Any miss on this narrative will disappoint Street (QIP raison d'être).
2 · Margin Resilience Under Pressure
EBITDA margin guidance of 12–13% is critical; any compression below 11% signals OEM pricing power or unfavourable mix-shift (lower-margin trading business). Watch for commodity cost inflation hedge commentary and pricing power commentary. Q1 FY26 EBITDA margin was 12.4%; beat or match is the bar.
3 · Hyva Acquisition Integration & Aerospace/Defence Progress
Hyva closed Aug 4; Q1 may show partial-quarter contribution (likely nil or marginal). Watch for integration timeline, cost synergies expected, and ROIC assumptions. Aerospace/defence vertical commentary (HSBC's thesis driver) will also influence rating/target sustainability. Any acceleration in this vertical could be a re-rating driver.
The Closing Frame
Belrise reports Q1 FY27 as a pivotal print: the first result post-capital raise and M&A, and the launchpad for the 40–45% 4W/CV growth narrative driving the QIP thesis. Street consensus is constructive (Buy/Accumulate at ₹250–₹270+), but the stock is technically overbought (RSI 77.1), leaving little room for guided-range prints to disappoint. Revenue in the ₹2,110–₹2,427 Cr range is expected; the swing factor is margin resilience (watch for OEM pricing pressure and trading-business mix) and management confidence on FY27 execution. Hyva integration and aerospace/defence progress updates will colour the rerating narrative. Strong print = revenue at midpoint+, margin 12%+, and FY27 guidance reaffirmed with capex deployment milestones; weak print = revenue miss, margin compression, or equivocal FY27 outlook.
Strong orders, flat margins—Belrise's execution test begins
Belrise announced seven major order wins and raised ₹17 Cr for M&A, but reported flat EBITDA margins (11.5%) despite 13% revenue growth. The gap between the order book depth and margin expansion claim is the quarter—and what unfolds in H2 will answer whether the stock's 8.75% sell-off is overdone or prescient.
₹2,546.5 Cr
+12.6% YoY
₹2,197.9 Cr
+20% YoY
₹293.3 Cr
+5% YoY; margin 11.5% flat
₹121.7 Cr
+8.9% YoY
The core tension
Belrise's quarter hinges on a gap that matters: revenue accelerated to +13% while operating profit growth lagged at +5%. Manufacturing revenue grew a robust 20% YoY, but EBITDA margins stayed flat at 11.5% despite this leverage—a red flag for margin expansion claims. Meanwhile, the trading business (14% of total revenue) contracted 19% YoY due to Middle East logistics and demand disruption, dragging consolidated growth from the underlying 13% to reported 12.6%. The core manufacturing story is genuinely strong; the cost inflation headwind is real, not yet offset by pricing, and execution on a backend-loaded order book begins now.
What management claimed vs. what holds up
Revenue growth 12-13% YoY; manufacturing growth much higher
Delivered 12.6% total, 20% manufacturing. Mid-teens guidance remains on track for FY27.
Supported
Worst of cost pressures behind us; margins to improve in coming quarters
Q1 EBITDA margin 11.5% flat vs year-ago, despite 13% revenue growth. EBITDA growth +5% lags revenue +13%. No evidence of cost pass-through yet.
Contradicted
Back-to-back pricing passes commodity inflation through with slight lag
Steel and polymer costs elevated Q1. Management stated back-to-back pricing model in place. But Q1 margin flat signals pricing not yet offsetting input cost rise.
Overstated
7 major order wins including ₹1.5B renewable energy and ₹650M two-wheeler chassis
Orders confirmed at ₹7.65B+ cumulative annual run rate. But 4 of 7 start production Q4 FY27 or later. No material Q1 revenue impact.
Supported (timing)
One fast-growing 2-3W OEM now ₹2B run rate (fuel tank, exhaust, chassis, suspension, braking)
Cumulative wins (last quarter + this quarter) total ~₹2B run rate. Mix headwind: 2-3W segment grew 18% YoY vs industry 20-25%.
Supported
What changed on this call
The bull-bear ledger
Manufacturing growth momentum: +20% YoY on strong OEM demand (2-3W, commercial vehicle, renewable energy, aerospace)
Order book depth: ₹7.65B+ annual run rate announced; expanding wallet-share with tier-1 OEMs across multiple segments
Strategic M&A underway (Hyva tipper close Q3, aerospace acquisitions prior). Deployment of ₹17 Cr capital raise toward inorganic growth
Flat margin despite 13% revenue growth: negative operating leverage raises doubt on cost inflation narrative
Backend loading: 4 of 7 major orders (₹2.65B+ run rate) start Q4 or later. Q2-Q3 revenue momentum at risk if execution falters
Trading business drag: -19% YoY (₹3.5B→₹2.8B est.) from Middle East crisis. Guidance vague; reliant on macro normalization
OEM concentration building: one fast-growing 2-3W OEM now ~8% of manufacturing revenue (₹2B run rate) on ₹27.5B base
Mid-teens FY27 revenue guidance on track (Q1 delivered 12.6%; manufacturing +20% offsetting trading -19%)
Risks, ranked by how much they should concern a holder
Order ramp execution: 4 of 7 wins (₹2.65B+ run rate) start Q4 or later. Production delays or yield issues could derail FY27 guidance.
HighBackend loading means Q2-Q3 revenue visibility is light. Any slip in Q4 ramp-up will compress FY27 growth and extend margin headwinds into next year.
Margin expansion unproven: Q1 EBITDA +5% vs revenue +13%. Cost pass-through claimed but not visible; staff cost peak and commodity normalization timing uncertain.
HighIf H2 cost normalization doesn't materialize or pricing lags commodity deflation, FY27 margins could stay flat or compress further. Stock repriced on margin expansion hope; any miss re-rates downward.
Hyva acquisition integration (close Q3): 3 facilities, new segment (tippers, systems), unproven synergy with Plasan defense opportunity.
HighOne-time close timing Q3 means integration risk overlaps with order ramps. Any post-close friction (facility redundancy, customer overlap, talent retention) could delay accretion or margin targets.
Trading business structural decline: -19% YoY from Middle East crisis. No FY27 guidance given; reliant on macro recovery outside management's control.
MediumTrading is ~14% of revenue; continued contraction would force manufacturing growth >15% to maintain mid-teens guidance. Headwind to narrative if macro stays stressed.
Single 2-3W OEM concentration: ₹2B run rate on one fast-growing OEM (~8% of manufacturing revenue). Market share gain but customer concentration risk if OEM faces competition.
MediumRapid ramp with one OEM creates wallet-share risk if OEM market position changes. Multi-product entry (5 categories) provides some hedge, but single-OEM revenue cliff is possible if relationship sours.
Geopolitical headwind to Plasan/defense: Israel tensions slow geopolitical progress. No orderbook visibility; opportunity sizing remains vague.
MediumDefense is part of 10% medium-term aerospace/defense narrative. Continued Middle East unrest could delay or shrink this tailwind, leaving M&A case to organic manufacturing alone.
How the street is positioned
The stock dropped 7.54% on day 1 post-result and traded down 8.75% by day 3—a material sell-off that suggests the market repriced on margin disappointment. The stock now trades at ₹231.77, below its 20-day (₹241.39) and 50-day (₹237.53) moving averages but still above its 200-day (₹198.56), putting it in neutral technical territory (RSI 41.2). The 52-week range is ₹142.59–₹268.2; at current levels the stock is off its all-time high by 13.58% but up 62.54% from the 52-week low—a meaningful recovery that now faces the test of whether that recovery was justified.
Ownership dynamics matter here: FII holdings rose 2.7 percentage points QoQ to 12.10% (from 9.40% in Q1), and DII holdings rose 3.11 percentage points to 13.12% (from 10.01%)—a combined institutional addition that signals confidence. But promoter shareholding fell 5.31 percentage points to 61.15% from 66.46%, a material dilution. The April 2026 bulk block sale (46 lakh shares at ₹213.33 via Jainam Broking) near the 52-week highs is a minor flag on insider/broker-linked selling, but not a smoking gun. The bigger signal: institutional *net buying* into a stock that just fell 8.75% suggests the market is finding the dip attractive despite margin concerns.
The disconnect is real: the sell-off prices in near-term execution risk (Q4 order ramps, margin headwinds persisting) and cash cost of the trading business drag. The buy-side addition signals longer-dated confidence in aerospace/defense M&A thesis and mid-teens growth delivery. The honest read is that *both* are right to some degree—the stock is correctly repriced lower on margin disappointment and backend loading, but the 8.75% dip is not catastrophic if management executes on H2 cost normalization and order production.
The debate
What to watch next
1 · Q2 manufacturing revenue and EBITDA margin—the early signal on cost pass-through
If margin expands even 50–75 bps YoY in Q2 (from 11.8% in Q1 prior year), it signals cost inflation is being offset by pricing. Flat or declining margin into Q2 suggests the H2 recovery is at risk.
2 · Hyva close timing and integration commentary (Q3)—proof the M&A thesis is on track
Close in Q3 FY27 is in guidance. Any delay (to Q4 or beyond) signals integration friction and re-rates the M&A accretion assumptions downward. Immediate revenue/EBITDA guidance for Hyva post-close is the credibility test.
3 · Q4 order ramp execution and ₹2.65B run-rate revenue contribution—backend loading vindication or risk
4 of 7 announced orders start Q4. Q4 sequential revenue growth >10% QoQ would validate the order execution story. Anything below that leaves FY27 mid-teens growth at risk and suggests execution challenges.
The close
Belrise is a steady story with near-term execution friction. The fundamentals (manufacturing growth, order book, M&A roadmap) are sound; the friction (flat margins, backend loading, trading drag) is real and priced into the 8.75% sell-off. This is not a step-change quarter—it's a validation of mid-term positioning with a near-term caution flag. Hold if you own it and are comfortable with Q4 execution risk. Add only if you have conviction on H2 cost normalization and can tolerate 3–6 months of margin uncertainty.
The single number to track from here is Q2-Q3 manufacturing EBITDA margin. If it expands toward 12.5%+ by Q3, the margin narrative re-rates the stock higher and validates management's H2 confidence. If it stays flat or rolls over, the stock trades sideways until Hyva close and Q4 order ramps prove execution.
Strong order wins overshadowed by flat margin, Q4-heavy ramps ahead
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Mid-teens guidance on track (12.6% in Q1), margin stability reaffirmed (11.5% flat vs FY26). However, margin expansion claims lack evidence; cost pass-through not visible in Q1.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Belrise is navigating a transition: strong order book and strategic aerospace/defense push offset by flat margins despite 13% revenue growth and trading business decline (-19% YoY). Mid-teens growth claim intact but dependent on Q4 ramp-ups; cost inflation confidence not yet proven in Q1 numbers. Key risk: execution on Hyva close (Q3) and order production ramps.
₹2546.5 Cr
Revenue · +12.6% YoY₹121.7 Cr
Reported PAT · +8.9% YoYFlat
Margins · vs guidance: MixedDid the claims hold up?
Revenue growth 13% YoY; PAT growth 9% YoY
OVERSTATEDDelivered 12.6% revenue YoY, 8.9% PAT YoY; manufacturing revenue 20% YoY
Worst of cost pressures behind us; margins to improve in coming quarters
MISSQ1 EBITDA margin flat at 11.5% despite 13% revenue growth; EBITDA only +5% YoY. Staff costs up from wage hike and facility pre-hiring.
Back-to-back pricing passes commodity inflation through with slight lag
OVERSTATEDQ1 margin flat vs year-ago; no evidence of pass-through benefiting margins yet. Management unable to quantify RM impact.
Two-wheeler/three-wheeler segment growing with this fast-growing OEM at ₹2B run rate
MET2-3W segment grew 18% YoY vs industry 20-25%; OEM concentration risk visible. Management acknowledged customer mix drag.
7 major order wins this quarter, including ₹1.5B renewable energy and ₹0.65B 2W chassis
METOrders confirmed but 4 of 7 start Q4 or later; no Q1 revenue impact. Future revenue dependent on ramp-up execution.
Earnings quality
What changed since the last call
Order book depth widened via new OEM penetration
UpgradeFast-growing 2-3W OEM moved from limited to ₹2B run rate (fuel tank, exhaust, chassis, suspension, braking). Renewable energy ₹1.5B entry. New capabilities (H-One 1470 MPa, tooling/automation).
Margin trajectory claim softened
DowngradePrior: expect mid-teens growth with margin expansion. Current: stable margins = flat 11.5% confirmed, but expansion deferred to H2 pending cost pass-through. Q1 EBITDA +5% vs revenue +13% shows near-term headwind.
Aerospace/defense 10% target reaffirmed
NeutralNo new quantification. Hyva acquisition (commercial vehicle) and aerospace M&A pipeline ongoing. Timing remains 'short to medium term' (vague).
Trading business decline acknowledged but isolated
Neutral19% decline attributed to Middle East crisis (logistics, demand). Guidance: 'worst behind us,' business to grow but slower than manufacturing. No specific FY27 target.
The Q&A
Analysts pressed hard on margin quantification (RM pass-through, labor, energy impact), manufacturing segment mix lag vs industry growth, trading business outlook, and defense/Plasan revenue opportunity. Management largely deflected specifics ('happy to discuss offline') and reiterated guidance, showing caution on near-term execution visibility.
2-3W order cumulation — Vipul Agrawal, HSBC Securities
AnsweredApproximately ₹1,550M cumulative (₹900M last quarter + ₹650M this quarter) plus suspension and braking wins on top. Total run rate now ~₹2,000M with this single OEM.
Renewable energy recurring revenue — Vipul Agrawal, HSBC Securities
AnsweredRecurring annual revenue at peak volumes. Initial entry 2.5 GW with room to expand. Production starts Q4 FY27, scales thereafter. Customer is market leader in solar trackers.
Margin trajectory quantification — Nitij Mangal, Jefferies
PartialCommodity pass-through in next quarters from Q1 pressure. Staff cost peak post-hiring for 4 new facilities. Energy normalized. Expect margins to rise H2 to maintain FY26 annual level.
2-3W growth vs industry lag — Shubham, Investec
AnsweredMix effect: faster OEMs not historically in customer base. New penetration (₹2B run rate) and order ramps Q3-Q4 will close the gap.
Trading business decline — Nitin Agarwal, JM Financial
PartialMiddle East crisis pressured volumes Apr-Jun. Worst behind us; business will grow but slower than manufacturing. No specific guidance.
H-One high-tensile TAM and trajectory — Vipul Agrawal, HSBC Securities
PartialAll sheet metal parts in 4-wheelers. EV OEM localization win (59 assemblies) uses H-One. Light-weighting and crash safety drivers. TAM under OEM discussion; no specific revenue guidance.
Plasan Sasa defense revenue opportunity — Vipul Agrawal, HSBC Securities
DodgedCurrently supplying parts to Plasan, exporting to Israel. Geopolitical challenges slow progress. Hyva acquisition synergistic for future but timing dependent on global stability. No orderbook disclosed.
Facility-specific utilization and ramp — Divyansh Jaju, Trinetra Asset Managers
DodgedUnable to comment on specific facility details. Guidance on overall numbers shared.
Guidance
FY27 mid-teens revenue growth
MediumQ1 delivered 12.6% YoY (lower end of mid-teens). Dependent on H2 ramps (4 major orders start Q4+). Manufacturing growth strong (20%) but trading drag (-19%) persists.
EBITDA margins stable as compared to FY26 levels (11.5%)
MediumQ1 margin 11.5% flat vs year-ago. Cost pass-through to materialize in H2; staff costs have peaked post-hiring. Expansion not guided, only stability.
Capex 6-6.5% of manufacturing revenue
HighMaintained from prior guidance. ₹17 Cr QIP deployed toward M&A (Hyva, aerospace acquisitions) and select organic initiatives.
Risks the call surfaced
Execution risk—order ramp delays
High4 of 7 orders (₹2.65B+ cumulative run rate) start Q4 FY27 or later. Delayed ramps or production issues could miss FY27 guidance.
Margin compression from cost inflation
MediumInput costs (steel, polymer) elevated; staff costs up (wage hike, pre-hiring). Q1 EBITDA growth (5%) lagged revenue (13%), signaling incomplete cost pass-through.
Trading business volatility
MediumTrading revenue -19% YoY due to Middle East crisis, logistics, and demand disruption. Represents ~14% of total revenue; dragged consolidated growth from 13% to 12.6%.
Customer concentration in 2-3 wheeler OEM
MediumOne fast-growing 2-3W OEM now represents ₹2 Cr run rate (~8% of manufacturing revenue). Historical limited presence; rapid ramp creates single-customer concentration risk.
Geopolitical—Plasan defense opportunity dependent on stability
MediumPlasan Sasa (Israeli armor, anti-ballistic) currently supplies via Belrise parts exports. Israel geopolitical tensions slow progress. Hyva fabrication synergy conditional on conflict de-escalation.
Management
Score 6/10. Strategic clarity on aerospace/defense and India localization tailwind is strong. But evasive on near-term: deflected RM quantification, margin bridge, facility specifics. Score 6/10 for transparency on execution. FY27 mid-teens guidance on track (12.6% Q1 delivered). Margin stability claimed but flat Q1 margin despite 13% growth raises doubt. Order book impressive (₹7.65B+ run rate) but mostly Q4+ ramps. Score 6/10 for credibility on cost pass-through.
1 · Q3 FY27
Hyva tipper acquisition closing; 3 manufacturing facilities add commercial vehicle scale
2 · Q4 FY27
4 major orders (₹2.65B+ annual run rate) ramp to production
3 · H2 FY27
Cost commodity pass-through materialize; margin expansion narrative tested
Key risk: execution on Hyva close (Q3) and order production ramps.
Belrise Q1 FY27: consolidated PAT up 8.9% YoY as revenue grows 12.6% but margins compress
PAT +8.94% YoY · revenue +12.57% · margins compressing · miss vs street
₹2,546.47 Cr
+12.57% YoY
₹121.67 Cr
+8.94% YoY
4.74%
-0.1pp YoY
₹1.37
Belrise Industries' consolidated Q1 FY27 (quarter ended June 30, 2026) print shows revenue of ₹2,546.5 Cr, up 12.6% YoY but down 0.3% QoQ, with PAT of ₹121.7 Cr, up 8.9% YoY but down 6.6% QoQ — profit growth trailed revenue growth, a margin story rather than a demand one. Against the ₹136-173 Cr PAT range and ₹2,110-2,427 Cr revenue range flagged in pre-result previews (Univest), the quarter was a mixed print: revenue came in above the estimate band while PAT missed the low end. Versus management's own Q4 FY26 guidance of mid-teens revenue growth with broadly stable EBITDA margins, the quarter came up short on both: revenue growth landed just under mid-teens at 12.6%, and margins compressed rather than held steady.
Q1 FY-2027 vs prior quarters
The margin squeeze is traceable to raw materials: cost of materials consumed rose to 67.7% of consolidated revenue from 63.3% a year ago (₹1,722.8 Cr vs ₹1,431.5 Cr), the main driver pulling EBITDA margin (OPM) down to 11.5% from 12.4% YoY (roughly flat sequentially against 11.4% in Q4 FY26). Employee costs also rose sharply, up 41.9% YoY to ₹115.3 Cr, consistent with integration-related headcount additions. Partially offsetting this, finance costs fell 42% YoY to ₹46.5 Cr from ₹80.0 Cr, in line with the balance-sheet deleveraging brokerages have flagged post-IPO — but that saving sits below the EBITDA line and could not offset the gross-margin squeeze, leaving net margin at 4.8% versus 4.9% a year ago. Basic EPS of ₹1.37 declined both YoY (₹1.50) and QoQ (₹1.53) despite the PAT increase, a function of the larger weighted-average share count from the FY26 IPO-era equity base; further EPS dilution is likely from Q2 FY27 as the ₹1,700 Cr QIP shares (7.72 Cr shares at ₹220, allotted July 17, 2026) enter the weighted-average count.
The stock went into the print at ₹255.35, up 10.6% over the past month of trading.
Management projects continued mid-teens revenue growth, maintaining broadly stable EBITDA margins compared to FY26 levels. They anticipate capital expenditure to remain between 6% to 6.5% of manufacturing revenue, supporting ongoing investments in capacity and capabilities. The company is strategically focused on expan
— This quarter: missed
Standalone (secondary) PAT of ₹114.3 Cr grew a faster 11.5% YoY versus consolidated's 8.9%, pointing to the subsidiaries — including the UK and France operations and H-One India — as the softer link this quarter. The board also proposed a final FY26 dividend of ₹0.55/share (11%) specifically on the QIP-allotted shares and raised authorised capital to ₹550 Cr, both housekeeping items tied to the July QIP. Strategically, the company closed its acquisition of Hyva India's tipper-body business (~$5.65 Mn, August 4, 2026) and, through step-down subsidiary Belrise UK Holdings, acquired Chester Hall Precision Engineering (£13.2 Mn) — a UK aerospace/defence precision-engineering business — both consistent with management's stated push into "high-value, complex segments like aerospace and defense" flagged on the Q4 FY26 call.
W1
Whether OPM recovers toward FY26's ~12% run-rate after slipping to 11.5% this quarter, against guidance for 'broadly stable' margins
W2
Full weighted-average EPS impact of the 7.72 Cr QIP shares (₹220 issue price, allotted July 17, 2026) from Q2 FY27 onward
W3
Progress of the H-One India and Badve Autocomps/Eximius NCLT amalgamation filings, and early integration numbers from the Hyva (~$5.65 Mn) and Chester Hall (£13.2 Mn) acquisitions